{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 29. Management of Peripheral T-Cell Lymphoma","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/525ca2a6\"></iframe>","width":"100%","height":180,"duration":3373,"description":"In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed: \n1. “How I Treat Peripheral T-cell Lymphoma?”:\nhttps://pubmed.ncbi.nlm.nih.gov/24615779/\n2. ECHELON-2- RCT of CHOP vs BV-CHP in CD30-positive peripheral T-cell lymphomas:\nhttps://pubmed.ncbi.nlm.nih.gov/34921960/\n\n3. Ro-CHOP Phase III study (LYSA): Romidepsin-CHOP vs CHOP in peripheral T-cell lymphoma:\nhttps://pubmed.ncbi.nlm.nih.gov/34843406/\n\n4. RCT of autologous vs allogeneic HSCT as part of 1st line therapy in poor risk peripheral T-cell lymphoma:\nhttps://pubmed.ncbi.nlm.nih.gov/33512419/\n\n5. A phase 2 biomarker-driven study of ruxolitinib in T-cell lymphomas:\nhttps://pubmed.ncbi.nlm.nih.gov/34653242/\n\n6. JACKPOT8 study: Selective JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma:\nhttps://ash.confex.com/ash/2020/webprogram/Paper134650.html","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}